Article

LADAR 6000 offers good visual outcomes

The LADAR 6000 excimer laser with high-speed ablation (Alcon) offers excellent visual outcomes, according to Ángel López Castro of Spain, speaking at the Alcon symposium.

The LADAR 6000 excimer laser with high-speed ablation (Alcon) offers excellent visual outcomes, according to Ángel López Castro of Spain, speaking at the Alcon symposium.

Dr López Castro conducted a study comparing conventional and custom treatments using the LADAR system. A total of 115 eyes were enrolled in the study with 110 receiving the custom LASIK and 14 the conventional treatment.

At three months, two-thirds of eyes in the custom group were within 0.25 D mean refractive spherical equivalent (MRSE) of their intended target, compared with around half of those in the conventional treatment group. 70% of eyes achieved a postoperative uncorrected visual acuity (UCVA) equal to or better than their preoperative best corrected visual acuity (BCVA) as opposed to just 57% of the conventionally treated group.

López Castro discussed what he sees as the benefits of the new system: more surgeon control, enhanced ergonomics, improved patient comfort. Finally he remarked on the LADAR 6000's speed; it is 50% faster than Alcon's previous system. Treatments can now be completed in less than 60 seconds, which may offer potential postoperative benefits.

Dr López Castro concluded that the LADAR 6000 is able to offer good visual outcomes for the patient whilst also offering the surgeon a more efficient, simpler-to-use system.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.